Generic Name and Formulations:
Cefepime (as HCl) 500mg, 1g, 2g; pwd for IV infusion or IM inj after reconstitution.
Indications for MAXIPIME:
Susceptible infections, including moderate-to-severe pneumonia, uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections (UTIs) including pyelonephritis, complicated intraabdominal in adults (w. metronidazole). Empiric therapy in febrile neutropenia.
When giving IV, infuse over 30mins. Pneumonia: 1–2g IV every 8–12hrs for 10 days. Skin and skin structures, severe UTIs: 2g IV every 12hrs for 10 days. Mild-to-moderate UTIs: 500mg–1g IV or IM every 12hrs for 7–10 days (IM only for UTIs caused by E. coli). Intraabdominal (use w. metronidazole): 2g IV every 8–12hrs for 7–10 days. Febrile neutropenia: 2g IV every 8hrs for 7 days or until neutropenia resolves. CrCl ≤60mL/min: reduce dose; see full labeling. Hemodialysis: give dose after each session. Continuous ambulatory peritoneal dialysis: give usual doses at 48hr intervals.
<2mos: not established. Not for use in serious infection when pathogen is or may be H. influenzae type b. 2mos–16yrs (≤40kg): 50mg/kg/dose every 12hrs (every 8hrs for P. aeruginosa pneumonia); do not exceed recommended adult dose. Severe UTIs, pneumonia, skin and skin structure: give IV for 10 days. Mild-to-moderate UTIs: give IV or IM for 7–10 days (IM only for UTIs caused by E. coli). Febrile neutropenia: give IV every 8hrs for 7 days or until neutropenia resolves.
Penicillin or other β-lactam allergy.
Renal impairment. Risk of neurotoxicity (esp. in renally-impaired); discontinue if occurs and treat appropriately. Renal or hepatic dysfunction, poor nutritional state, prolonged antimicrobial therapy: monitor prothrombin time. History of GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Aminoglycosides may potentiate oto- or nephrotoxicity. Possible nephrotoxicity with diuretics (eg, furosemide). May cause false (+) Coomb's, Clinitest.
Local reactions (eg, pain, phlebitis, inflammation), rash, nausea, vomiting, diarrhea, pruritus, fever, headache, anemia, renal dysfunction; neurotoxicity, C. difficile associated diarrhea, hypersensitivity reactions.
Vials (500mg)—10; 1g, 2g—10, 25
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Oxidized Low-Density Lipoprotein May Predict Risk for Recurrent Stroke
- Inappropriate Prescribing Protocols in Parkinson Disease
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Congress Passes Bill to Fight Opioid Crisis